{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:13:06Z","timestamp":1773029586282,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,10]],"date-time":"2013-09-10T00:00:00Z","timestamp":1378771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["currenttherapeuticres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.curtheres.2013.08.001","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T03:41:08Z","timestamp":1381462868000},"page":"48-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study"],"prefix":"10.1016","volume":"75","author":[{"given":"Xue-jia","family":"Zhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-ning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2013.08.001_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11207600-000000000-00000","article-title":"Repaglinide: a review of its use in type 2 diabetes mellitus","volume":"72","author":"Scott","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.curtheres.2013.08.001_bib2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1463-1326.2008.00907.x","article-title":"Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes","volume":"10","author":"Raskin","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.curtheres.2013.08.001_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00129784-200707050-00002","article-title":"Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review","volume":"7","author":"Johansen","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.curtheres.2013.08.001_bib4","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.clinthera.2011.10.020","article-title":"Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review","volume":"33","author":"Germino","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2013.08.001_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0091270002239702","article-title":"Pharmacokinetics of repaglinide in healthy Caucasian and Japanese subjects","volume":"43","author":"Thomsen","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2013.08.001_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s002280100280","article-title":"Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment","volume":"57","author":"Schumacher","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2013.08.001_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0149-2918(00)88321-6","article-title":"Repaglinide pharmacokinetics in healthy young adult and elderly subjects","volume":"21","author":"Hatorp","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.curtheres.2013.08.001_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2125.2005.02516.x","article-title":"The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide","volume":"61","author":"Bidstrup","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2013.08.001_bib9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/0091270003253704","article-title":"Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide","volume":"43","author":"Hatorp","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2013.08.001_bib10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/clpt.2008.74","article-title":"Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism","volume":"84","author":"Kalliokoski","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2013.08.001_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/FPC.0b013e32830d733e","article-title":"Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide","volume":"18","author":"Kalliokoski","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.curtheres.2013.08.001_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000336345","article-title":"The influence of MDR1 G2677T\/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers","volume":"89","author":"Xiang","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/j.curtheres.2013.08.001_bib13","unstructured":"Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Silver Spring, Md: US Food and Drug Administration, Center for Drug Evaluation and Research; 2003."},{"key":"10.1016\/j.curtheres.2013.08.001_bib14","first-page":"562","article-title":"Functions of the DAS software for pharmacological calculation","volume":"7","author":"Chen","year":"2002","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2013.08.001_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.curtheres.2013.08.001_bib16","unstructured":"Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Silver Spring, Md: US Food and Drug Administration, Center for Drug Evaluation and Research; 2001."},{"key":"10.1016\/j.curtheres.2013.08.001_bib17","first-page":"636","article-title":"Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers","volume":"36","author":"Hatorp","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2013.08.001_bib18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00228-012-1453-9","article-title":"Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals","volume":"69","author":"Fu","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.curtheres.2013.08.001_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clpt.2004.12.267","article-title":"Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance","volume":"77","author":"Totah","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2013.08.001_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/00498250400021796","article-title":"Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers","volume":"35","author":"Yamaori","year":"2005","journal-title":"Xenobiotica"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X13000222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X13000222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T15:44:35Z","timestamp":1716047075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X13000222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":20,"alternative-id":["S0011393X13000222"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2013.08.001","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2013.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}